Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Stefan Aebi et al.|The Lancet Oncology|2017Cited by 122
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancerHannelore Denys, Mona M. Van Steenberghe, Corina L. Martinez-Mena et al.|Breast Cancer Research and Treatment|2020Cited by 44